25 Or More Amino Acid Residues In Defined Sequence Patents (Class 530/324)
-
Patent number: 11976274Abstract: Provided herein, are methods of identifying neoantigens for treating and preventing cancer. Also disclosed are methods and compositions for administering identified neoantigens for the treatment and prevention of cancer.Type: GrantFiled: March 28, 2022Date of Patent: May 7, 2024Assignee: Arizona Board of Regents on Behalf of Arizona State UniversityInventors: Stephen Albert Johnston, Luhui Shen
-
Patent number: 11963996Abstract: Knee pain caused by osteoarthritis is relieved by modifying the shape change of bone(s) underlying articular cartilage, by a method comprising evaluating the bone shape of the patient's joint, injecting the patient with a peptide of SEQ ID No. 1 or applying other therapeutic interventions that can reduce the shape change of the bone(s) underlying articular cartilage, and thereafter evaluating the bone shape of the patient's joint.Type: GrantFiled: September 27, 2019Date of Patent: April 23, 2024Assignee: ORTHOTROPHIX, Inc.Inventors: Yoshinari Kumagai, Dawn McGuire, Meghan Miller, David Rosen
-
Patent number: 11938168Abstract: The present invention encompasses ophthalmic compositions that may be used for various conditions of the eye, and particularly, conditions of the cornea. Also encompassed are methods that utilise these compositions and kits that include these compositions.Type: GrantFiled: October 23, 2020Date of Patent: March 26, 2024Assignee: Auckland Uniservices LimitedInventors: Colin Green, Carol Ann Greene, Trevor Sherwin
-
Patent number: 11906530Abstract: Methods are disclosed herein for determining whether a subject has a Tauopathy, such as Pick disease, Alzheimer disease, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) or argyrophilic grain disease (AGD). These methods utilize an amyloid seeding assay.Type: GrantFiled: December 29, 2017Date of Patent: February 20, 2024Assignee: The United States of America, as represented by the Secretary Department of Health and Human ServicesInventors: Byron Winslow Caughey, Eri Saijo, Allison Lindsey Kraus, Michael Anthony Metrick, II
-
Patent number: 11896674Abstract: An siRNA conjugate having a structure as represented by formula (1) for inhibiting hepatitis B vims gene expression, comprising siRNA and a conjugated group, wherein the sense strand of the siRNA comprises a nucleotide sequence 1, and the antisense strand comprises a nucleotide sequence 2; the nucleotide sequence 1 and the nucleotide sequence 2 are, at least in part, reversely complementary to form a double-stranded region; the nucleotide sequence 1 and SEQ ID NO: 1 are equal in length and differ by no more than three nucleotides; the nucleotide sequence 2 and SEQ ID NO: 2 are equal in length and differ by no more than three nucleotides. The siRNA conjugate can specifically target liver cells and effectively solve the problem of siRNA delivery in vivo, and shows excellent activity and low toxicity to inhibit HBV gene expression while maintaining high stability of siRNA.Type: GrantFiled: August 20, 2019Date of Patent: February 13, 2024Assignee: SUZHOU RIBO LIFE SCIENCE CO., LTD.Inventors: Hongyan Zhang, Shan Gao, Daiwu Kang, Gengrong Chen
-
Patent number: 11873468Abstract: Catechol-group-containing polymers with amine or amide functionality, containing at least one repeating unit of the formula (I) and at least one repeating unit of the formula (II) and optionally further repeating units The repeating units of the formula (II) are different from the repeating units of the formula (I) and the molar ratio of the units of the formula (I) to the units of the formula (II) is in the range from 0.5-to-1 to 4-to-1, are suitable for the dirt-repellent finishing of substrate surfaces, particularly surfaces of textiles, glass, ceramics or plastics. The polymers have an excellent adhesion to these surfaces, so that during cleaning of a substrate surface they adsorb to the substrate surface from the aqueous cleaning or washing liquor and realize their effect.Type: GrantFiled: June 18, 2020Date of Patent: January 16, 2024Assignee: Henkel AG & Co. KGaAInventors: Nils Wedler, Christian Kropf, Laura Hartmann, Stefan Schmidt, Lukas Fischer, Alexander Strzelczyk
-
Patent number: 11821904Abstract: The invention provides a method of identifying a peptide interaction site on a target protein wherein the target protein modulates the phenotype of a mammalian cell, using mammalian encoded peptides (SEPs) such as short open reading frame (sORF) encoded peptides. The invention further provides a method for the identification of new therapeutic targets and protein interaction sites for use in drug discovery.Type: GrantFiled: June 30, 2021Date of Patent: November 21, 2023Assignee: Phoremost LimitedInventors: Bryn Shaun Hardwick, Grahame James Mckenzie
-
Patent number: 11793857Abstract: Compounds, pharmaceutical compositions, and a method of treating hard tissue diseases and disorders are disclosed. The compounds may be a peptide and is structured to bind integrin ?v?3 expressed by osteocytes and by selective binding to the cell surface integrin on hard tissue forming cells regulate three-dimensional bone shape, cartilage formation and repair.Type: GrantFiled: September 17, 2021Date of Patent: October 24, 2023Assignee: ORTHOTROPHIX, INC.Inventors: Yoshinari Kumagai, Dawn McGuire, Meghan Miller, David Rosen
-
Patent number: 11793861Abstract: The present invention relates to PTH prodrugs, pharmaceutical compositions comprising such PTH prodrugs and their uses.Type: GrantFiled: November 8, 2022Date of Patent: October 24, 2023Assignee: ASCENDIS PHARMA BONE DISEASES A/SInventors: Kennett Sprogøe, Felix Cleemann, Guillaume Maitro, Mathias Krusch, Thomas Wegge, Joachim Zettler
-
Patent number: 11787837Abstract: The present invention relates to a novel acylating agent, a method for its preparation, and a method of using it for acylating one or more amino groups of an amino acid, a peptide, or a protein. The novel acylating agent may be a compound which comprises a structural element —HN—(CH2)2-(O—((CH2)2)k-O—(CH2)n-CO—, wherein k is an integer in the range of 1-10, and n is an integer in the range of 1-2, being esterified at its —CO-end to the hydroxy group of 3,5-dichloro-2-hydroxy-benzenesulfonic acid (3,5-DC-2-HBSA). This novel acylating agent has an improved stability. Using this agent the acylation process is improved as regards robustness, as well as improving yield and overall production economy. The novel acylating agent is useful for acylating pharmaceutical peptides and proteins such as GLP-1, insulin, pYY, and amylin. The invention also relates to a number of novel GLP-1 precursor peptides and derivatives in which the two N-terminal amino acids have been deleted.Type: GrantFiled: November 7, 2017Date of Patent: October 17, 2023Assignee: Novo Nordisk A/SInventors: Kim Birkebaek Jensen, Magnus Bernt Fredrik Gustafsson
-
Patent number: 11718650Abstract: The present invention provides novel peptides and homologues thereof. The peptides of the invention comprise (i) a T-cell epitope of an antigen (self or non-self) with a potential to trigger an immune reaction presented by a class II major histocompatibility complex (MHC) determinant and recognised by CD4+ T cell more specifically of an allergen or auto-antigen, coupled, optionally through the use of a linker to (ii) an amino acid sequence having a reducing activity, such as a thioreductase sequence. The peptides of the invention have been shown to be useful a medicine, more in particular for the prevention or treatment of immune disorders, more specifically of allergic disorders or autoimmune diseases. The present invention thus provides for the use of said peptides for the manufacture of a medicament for the prevention or treatment of an immune disorder and further provides for methods of treatment or preventing immune disorders by using said peptides.Type: GrantFiled: April 14, 2020Date of Patent: August 8, 2023Assignee: IMCYSE SAInventor: Jean-Marie Saint-Remy
-
Patent number: 11718649Abstract: The present invention is based on the fusion of FimH, CsgA and PapG adhesins (type 1 Fimbriae, curli and P, respectively) to generate biomolecules that can be used as vaccines against UTIs. Briefly, the invention is based on the design of a fusion template gene fimH-csgA-papG-fimH-csgA and defined as fcpfc to generate the different combinations of monomeric [FimH, CsgA and PapG], dimeric [FimH-CsgA (FC), CsgA-PapG (CP) and PapG-FimH (PF)] and trimeric (FimH-PapG-CsgA (FCP), PapG-CsgA-FimH (PCF) and CsgA-FimH-PapG (CFP)] proteins. Bioactivity was determined by the antibodies present in UP sera and urine, the quantification in the release of cytokines and adhesion inhibition assays.Type: GrantFiled: October 11, 2018Date of Patent: August 8, 2023Inventors: Juan Xicohtencatl Cortes, Victor Manuel Luna Pineda
-
Patent number: 11708390Abstract: The present invention concerns a method of storing a separation matrix comprising multimers of immunoglobulin-binding alkali-stabilized Protein A domains covalently coupled to a porous support. The method comprises the steps of: a) providing a storage liquid comprising at least 50% by volume of an aqueous alkali metal hydroxide solution; b) permeating the separation matrix with the storage liquid; and c) storing the storage liquid-permeated separation matrix for a storage time of at least days.Type: GrantFiled: May 10, 2017Date of Patent: July 25, 2023Assignee: Cytiva BioProcess R&D ABInventors: Annika Forss, Gustav José Rodrigo, Tomas Bjorkman, Mats Ander, Jesper Ulf Hansson
-
Patent number: 11684674Abstract: The invention provides formulations for oral delivery of a therapeutic agent wherein the formulation comprises a kappa opioid receptor agonist and an absorption enhancer, the absorption enhancer includes a medium chain fatty acid or a salt of a medium chain fatty acid; and a medium chain fatty acid glyceride. The kappa opioid receptor agonist may be embedded in an oligosaccharide, such as trehalose. Also provided are capsules containing the oral formulations of the kappa opioid receptor agonists and the absorption enhancer of the invention and methods use of these formulations for the prophylaxis and treatment of variety of kappa opioid receptor-associated diseases and conditions such as pain, pruritus and inflammation; the method comprising administering to the mammal the formulation comprising the kappa opioid receptor agonist and an absorption enhancer.Type: GrantFiled: April 28, 2021Date of Patent: June 27, 2023Assignee: Cara Therapeutics, Inc.Inventors: Bryan R. Wilson, Stephen J. O'Connor
-
Patent number: 11660347Abstract: The present disclosure provides a siRNA for inhibiting the expression of apolipoprotein C3 (ApoC3) gene, and a pharmaceutical composition and a conjugate comprising the siRNA; wherein each nucleotide in the siRNA is independently a modified nucleotide, and the siRNA comprises a sense strand and an antisense strand; the sense strand comprises a nucleotide sequence A, the nucleotide sequence A having the same length as the nucleotide sequence as represented by SEQ ID NO:1 with no more than 3 nucleotide differences; the antisense strand comprises a nucleotide sequence B, the nucleotide sequence B having the same length as the nucleotide sequence as represented by SEQ ID NO:2 with no more than 3 nucleotide differences.Type: GrantFiled: November 29, 2018Date of Patent: May 30, 2023Assignee: SUZHOU RIBO LIFE SCIENCE CO., LTD.Inventors: Hongyan Zhang, Shan Gao, Daiwu Kang
-
Patent number: 11660550Abstract: There is disclosed a relatively simple method to increase the performance of surface localised multi-valent affinity ligands whose target's isoelectric pH differs significantly from the ligand's optimal target-binding pH. This situation can result in ligand binding of target affecting local pH and subsequent binding of more target. Increasing the buffering capacity of the ligand via recombinant or other addition of charge groups to the ligand is expected to partially offset such effects, leading to enhanced binding capacity as well as possible secondary favourable alterations in regard to ligand elution pH, and non-specific surface binding of non-target proteins.Type: GrantFiled: March 6, 2018Date of Patent: May 30, 2023Assignee: JMVA BIOTECH ABInventor: James M. Van Alstine
-
Patent number: 11643443Abstract: Methods of making engineered protein-based materials, nanofibers, and biofilms from bacterial amyloid-based structures that are capable of mediating long-range electron transport are provided.Type: GrantFiled: November 18, 2016Date of Patent: May 9, 2023Assignee: President and Fellows of Harvard CollegeInventors: Neel Satish Joshi, Noémie-Manuelle Dorval Courchesne
-
Patent number: 11633482Abstract: A compound for forming a conjugate with an active agent such as an oligonucleotide having a structure represented by Formula (321). The present disclosure also provides a corresponding conjugate. The conjugate of the present disclosure can specifically target hepatocytes, thereby effectively solve the problems associated with delivery of oligonucleotide drugs in vivo, and have low toxicity and excellent delivery efficiency while maintaining high stability for the delivered oligonucleotide.Type: GrantFiled: November 29, 2018Date of Patent: April 25, 2023Assignee: SUZHOU RIBO LIFE SCIENCE CO., LTD.Inventors: Hongyan Zhang, Zhiwei Yang, Liqiang Cao, Liangyi Wan
-
Patent number: 11608359Abstract: The present invention provides Larazotide derivative compositions that resist protease degradation, and in various embodiments, do not demonstrate an inverse dose response, and/or can be delivered at higher doses without loss of potency or efficacy, thereby allowing improved therapy and more desirable dosing schedules.Type: GrantFiled: February 25, 2019Date of Patent: March 21, 2023Assignee: 9 Meters Biopharma, Inc.Inventors: Jay P. Madan, Balasingham Radhakrishnan, Sandeep Laumas, Christopher Prior
-
Patent number: 11608511Abstract: Compositions and methods concern the sequence modification of an endogenous genomic DNA region. Certain aspects relate to a method for site-specific sequence modification of a target genomic DNA region in cells comprising: contacting the cells with an activating composition; transfecting the cells with a transfection composition comprising (a) donor DNA and (b) a DNA digesting agent; wherein the donor DNA comprises: (i) a homologous region comprising nucleic acid sequence homologous to the target genomic DNA region; and (ii) a sequence modification region; and wherein the genomic DNA sequence is modified specifically at the target genomic DNA region.Type: GrantFiled: April 13, 2016Date of Patent: March 21, 2023Assignee: MaxCyte, Inc.Inventors: Linhong Li, Madhusudan Peshwa
-
Patent number: 11608414Abstract: The present invention provides peptoid polymers and salts thereof that comprise hydrophobic and polar peptoid monomers and are capable of reducing or inhibiting the formation of ice crystals at sub 0° C. temperatures. Also provided are peptoid-peptide hybrids and salts thereof comprising the peptoid polymers provided herein. The peptoid polymers, peptoid-peptide hybrids, and salts thereof provided herein are useful for making cryoprotectant solutions. The peptoid polymers, peptoid-peptide hybrids, salts thereof, and cryoprotectant solutions provided herein are useful for making antifreeze solutions, frozen food products, and cosmetic care products. Also provided herein are methods for preserving a tissue, an organ, a cell, or a biological macromolecule using the compositions described herein.Type: GrantFiled: September 26, 2019Date of Patent: March 21, 2023Assignee: X-THERMA, INC.Inventor: Xiaoxi Wei
-
Patent number: 11578110Abstract: The present disclosure provides peptides, or variants or analogs thereof, with between 8 and 30 amino acids, having growth factor receptor-binding capability, wherein the RMSD value of the structure coordinates of said peptide, variant or analog thereof with respect to PEPREF is 2.45 ? (Angstroms) or less.Type: GrantFiled: August 25, 2016Date of Patent: February 14, 2023Assignee: HISTIDE AGInventor: Omar F. Zouani
-
Patent number: 11566082Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of an Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO 26 or SEQ ID NO 27, wherein at least the alanine residue at the position corresponding to position 42 in SEQ ID NO:4-7 has been mutated to arginine and/or wherein at least the aspartic acid residue at the position corresponding to position 37 in SEQ ID NO:4-7 has been mutated to glutamic acid.Type: GrantFiled: November 11, 2015Date of Patent: January 31, 2023Assignee: Cytiva BioProcess R&D ABInventors: Gustav Rodrigo, Tomas Bjorkman, Mats Ander
-
Patent number: 11564388Abstract: The present invention provides methods for cryopreserving a population of cells with improved cell viability. In some aspects, the method comprises contacting a population of cells with a peptoid polymer comprising one or more polar peptoid monomers, e.g., formulated in a cryoprotectant solution, and cooling the population of cells at a temperature of from 0° C. to about ?20° C. for a time period of at least about 3 hours to produce a population of supercooled cells. The supercooling methods of the present invention provide excellent post-thaw cell survival and recovery. In certain embodiments, the population of cells is present in a tissue or an organ that is cryopreserved by performing the supercooling methods of the present invention.Type: GrantFiled: September 26, 2019Date of Patent: January 31, 2023Assignee: X-THERMA, INC.Inventor: Xiaoxi Wei
-
Patent number: 11535654Abstract: The present invention addresses the problem of providing: a fusion protein or conjugated protein having excellent cell membrane permeability, containing a partial peptide derived from human, and suitable for intracellular delivery; an intracellular delivery carrier comprising such a fusion protein or conjugated protein; a partial peptide; a cell membrane permeation enhancer comprising the partial peptide; DNA; and a vector. The fusion protein or conjugated protein has a partial peptide comprising at least seven consecutive amino acid residues of an amino acid sequence encoded by a predetermined DNA, and a ligand directly or indirectly bound to the partial peptide and having the capability of binding to cell surfaces. The ligand is preferably an antibody. The intracellular delivery carrier comprises the fusion protein or conjugated protein. The cell membrane permeation enhancer comprises the partial peptide.Type: GrantFiled: June 2, 2016Date of Patent: December 27, 2022Assignee: Keio UniversityInventors: Kei Sudo, Keisuke Niikura, Nobuhide Doi
-
Patent number: 11524984Abstract: A recombinant spider silk protein, consisting of no more than 800 amino acids, comprising a set of domains arranged according to the formula (NT)-REP-CT, wherein: the optional NT-domain, if present, comprises a sequence of 100 to 160 amino-acid residues derived from the N-terminal domain of a spider silk protein; the REP-domain comprises a sequence of 30 to 600 amino acid residues derived from the repetitive segment of a spider silk protein; and the CT-domain comprises a sequence of 70 to 120 amino acid residues derived from the C-terminal domain of a spider silk protein selected from: a sequence of 72 to 110 amino acid residues derived from the C-terminal domain of a spider silk protein, wherein the sequence comprises at least 7 residues independently selected from K, R, E and D; a sequence having at least 85% identity to SEQ ID NO: 15 or any one of SEQ ID NOs: 62-65 or 67-73; and a sequence having at least 70% identity to SEQ ID NOs: 64 or any one of SEQ ID NOs: 62-65 or 67-73, wherein the sequence compriseType: GrantFiled: June 29, 2017Date of Patent: December 13, 2022Assignee: SPIBER TECHNOLOGIES ABInventors: Anna Rising, Jan Johansson, Marlene Andersson
-
Patent number: 11524986Abstract: Compositions and methods for the inhibiting human growth hormone (hGH), and treating or preventing hGH-mediated disorders, using a S1H peptide having the amino acid sequence of [SEQ ID NO: 1], or a variant thereof, are described.Type: GrantFiled: July 10, 2019Date of Patent: December 13, 2022Assignee: Ohio UniversityInventors: Justin M. Holub, John J. Kopchick, Reetobrata Basu
-
Patent number: 11484521Abstract: The present application provides, inter alia, a compound of Formula (I): or a pharmaceutically acceptable salt thereof, and methods of use of the compound of Formula (I) for treatment and prevention of cyanide poisoning.Type: GrantFiled: April 12, 2018Date of Patent: November 1, 2022Assignees: The General Hospital Corporation, The Regents of the University of CaliforniaInventors: Randall Peterson, Robert Gerszten, Anjali Nath, Calum MacRae, Gerry Boss, Matt Brenner, Sari Brenner Mahon
-
Patent number: 11446356Abstract: Engineered peptides that bind with high affinity (low equilibrium dissociation constant (Kd)) to the cell surface receptors of fibronectin (?5?1) or vitronectin (?v?3 and ?v?5 integrins) are disclosed as useful as imaging tissue. These peptides are based on a molecular scaffold into which a subsequence containing the RGD integrin-binding motif has been inserted. The subsequence (RGD mimic) comprises about 9-13 amino acids, and the RGD contained within the subsequence can be flanked by a variety of amino acids, the sequence of which was determined by sequential rounds of selection (in vitro evolution). The molecular scaffold is preferably based on a knottin, e.g., EETI (Trypsin inhibitor 2 (Trypsin inhibitor II) (EETI-II) [Ecballium elaterium (Jumping cucumber)], AgRP (Agouti-related protein), and Agatoxin IVB, which peptides have a rigidly defined three-dimensional conformation. It is demonstrated that EETI tolerates mutations in other loops and that the present peptides may be used as imaging agents.Type: GrantFiled: February 28, 2020Date of Patent: September 20, 2022Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jennifer R. Cochran, Richard H. Kimura, Aron M. Levin
-
Patent number: 11413327Abstract: A method of alleviating joint pain in a patient comprising evaluating the patient's joint pain when undergoing motions associated stress to the joint, and injecting the patient with a peptide of SEQ ID No. 1, and thereafter evaluating the patient's joint pain when undergoing the same motion.Type: GrantFiled: October 30, 2020Date of Patent: August 16, 2022Assignee: ORTHOTROPHIX, INC.Inventors: Yoshinari Kumagai, Dawn McGuire, Meghan Miller, David Rosen
-
Patent number: 11389505Abstract: A method of alleviating joint pain in a patient comprising evaluating the patient's joint pain when undergoing motions associated stress to the joint, and injecting the patient with a peptide of SEQ ID No. 1, and thereafter evaluating the patient's joint pain when undergoing the same motion.Type: GrantFiled: October 9, 2020Date of Patent: July 19, 2022Assignee: ORTHOTROPHIX, INC.Inventors: Yoshinari Kumagai, Dawn McGuire, Meghan Miller, David Rosen
-
Patent number: 11382968Abstract: Provided in the present disclosure are immunogenic compounds, pharmaceutical formulations thereof and their use for inducing a protective immune response against 2019 novel coronavirus (SARS-CoV-2) infection and variants in a mammal.Type: GrantFiled: June 9, 2021Date of Patent: July 12, 2022Assignee: Altimmune Inc.Inventors: Bertrand Victor Gilbert Georges, M. Scot Roberts
-
Patent number: 11358994Abstract: The disclosure provides for new epidermal growth factor (EGF)-based reagents that have been modified by fatty acid conjugation. Method of using such agents to treatment Short Bowel Syndrome (SBS) are also described.Type: GrantFiled: July 25, 2018Date of Patent: June 14, 2022Assignee: Saint Louis UniversityInventors: Marvin J. Meyers, David C. Wood, Stacy D. Arnett, Matthew P. Yates, Peter G. Ruminski
-
Patent number: 11319341Abstract: Doxorubicin derivatives for targeted activation by Legumain, its preparation method and use. The doxorubicin derivatives are obtained by condensation between the amino group of compound A and the carboxyl group of compound B and have the following structure: compounds A and B have the following structures, respectively: wherein R3 in compound B is Leu or absent; R4 is any one amino acid selected from the group consisting of Ala and Thr; R5 is any one amino acid selected from the group consisting of Ala, Thr and Asn; R6 is wherein n=1-20; or wherein R7 is substituted or unsubstituted, linear or branched, saturated or unsaturated C1-C20 fatty hydrocarbon, or substituted or unsubstituted C6-C20 aromatic hydrocarbon. The doxorubicin derivatives of the present invention are specifically tumor-targeted and have a long in vivo metabolic half-life, as compared with doxorubicin. They exhibit an efficient and safe anti-tumor effect and could be used to prepare an anti-tumor drug.Type: GrantFiled: February 20, 2020Date of Patent: May 3, 2022Assignee: Yafei (Shanghai) Biopharmaceutical Co., Ltd.Inventors: Cheng Liu, Yuan Liu
-
Patent number: 11285169Abstract: Methods of reducing cytotoxicity of a chemotherapeutic agent to non-cancer cells by administering to a subject with cancer an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent, such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are provided. Example disclosed methods reduce cardiotoxicity. In one example, the methods include administering to a subject with cancer an effective amount of a CD47 antisense morpholino oligonucleotide and an anthracycline such as doxorubicin. Methods of increasing cytotoxicity of a chemotherapeutic agent in cancer cells by administering to a subject with a tumor an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are also provided. In some embodiments, the inhibitor of CD47 signaling is administered to the subject before, during, or after the administration of the DNA damaging agent.Type: GrantFiled: March 13, 2014Date of Patent: March 29, 2022Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: David D. Roberts, David R. Soto Pantoja
-
Patent number: 11253617Abstract: A method of preparing a 64Cu-BaBaSar-RGD2 solution is provided. The method includes lyophilizing a solution of BaBaSar-RGD2 and adding a 64Cu solution to the lyophilized BaBaSar-RGD2.Type: GrantFiled: November 30, 2018Date of Patent: February 22, 2022Assignee: University of Southern CaliforniaInventors: Shuanglong Liu, Peter Conti
-
Patent number: 11230576Abstract: The present invention relates to immunoglobulin (Ig) binding proteins comprising one or more Ig binding domains with amino acids selected from the group consisting at least of 1I, 11A, 11E, 11I, 35R, 35I, and 42L. The invention further relates to affinity matrices comprising the Ig binding proteins of the invention. The invention also relates to a use of these Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Ig binding proteins of the invention.Type: GrantFiled: August 7, 2017Date of Patent: January 25, 2022Assignee: Navigo Proteins GmbHInventors: Paul Knick, Erik Fiedler, Ulrich Haupts, Maren Meysing
-
Patent number: 11214624Abstract: Compositions and methods for inhibiting cancer cell metastasis and inflammation are disclosed. The methods generally involve administering to a subject a composition containing an agent that selectively inhibits the binding of p68 RNA helicase to calmodulin (CaM) in the cells.Type: GrantFiled: March 13, 2013Date of Patent: January 4, 2022Assignee: Proda Biotech LLCInventors: Zhi-Ren Liu, Haizhen Wang
-
Patent number: 11149061Abstract: A method of purifying an antifreeze protein (AFP) and methods of producing AFPs are disclosed. The method of purifying an AFP includes heating a crude AFP in an aqueous medium to a temperature and for a length of time sufficient to precipitate at least some thermally unstable proteins in the crude AFP and form a precipitate and a supernatant; and removing the precipitate from the supernatant. One method of producing an AFP includes collecting a crude source of the AFP; and purifying the AFP by the purification method. Another method of producing an AFP includes growing or culturing a host configured to express a recombinant AFP in a growth medium, and collecting a crude AFP from the host and/or the growth medium. The growth medium comprises water, a protein hydrolysate or other source of amino acids, a yeast extract, a biologically metabolizable C3-C6 polyol, and one or more phosphate salts.Type: GrantFiled: December 27, 2019Date of Patent: October 19, 2021Assignees: The Board of Trustees of the California State University, California State University, Los AngelesInventor: Xin Wen
-
Patent number: 11124547Abstract: Computational systems and methods are described for identifying new type-ll bacteriocins using a systemic consensus formula and other related criteria. Newly identified type-ll bacteriocin peptides are tested experimentally and show potent microbicidal activities. Further provided are the sequences of Newly identified type-ll bacteriocin peptides, and a method of treating an infection in a patient in need thereof, comprising administering to the patient an effective amount of a peptide comprising an amino acid sequence disclosed.Type: GrantFiled: May 10, 2018Date of Patent: September 21, 2021Assignee: THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATIONInventors: Nannette Y. Yount, Michael R. Yeaman
-
Patent number: 11090398Abstract: Methods and devices for sterilizing viscous peptide compositions which have shear thinning rheological properties at high concentrations.Type: GrantFiled: October 26, 2018Date of Patent: August 17, 2021Assignee: 3-D Matrix, Ltd.Inventors: Eun Seok Gil, Karl Patrick Gilbert
-
Patent number: 11066449Abstract: Improved electrically conductive pili were generated from a natural pilus protein from the microorganism Geobacter sulfurreducens. Substituting a tryptophan for the phenylalanine at position F51 and a tryptophan for the tyrosine at position Y57 of the pilus monomer substantially increased the conductivity of the pili and reduced their diameter to 1.5 nm. Substantial improvements in conductivity were also achieved by substituting an additional tyrosine, histidine, and phenylalanine in the pilus monomer to mimic the monomer of Geobacter metallireducens, but the pili retained the typical Geobacter sulfurreducens wild-type diameter of 3 nm.Type: GrantFiled: July 19, 2016Date of Patent: July 20, 2021Assignee: University of MassachusettsInventors: Derek R. Lovley, Nikhil Malvankar, Ramesh Adhikari, Yang Tan, Joy Ward, Kelly Nevin
-
Patent number: 11041013Abstract: The invention is related to peptide constructs, i.e.Type: GrantFiled: March 16, 2009Date of Patent: June 22, 2021Assignee: Cel-Sci CorporationInventor: Daniel H. Zimmerman
-
Patent number: 10975388Abstract: Provided are methods and compositions for delivering a nucleic acid, protein, and/or ribonucleoprotein payload to a cell. Also provided are delivery molecules that include a peptide targeting ligand conjugated to a protein or nucleic acid payload (e.g., an siRNA molecule), or conjugated to a charged polymer polypeptide domain (e.g., poly-arginine such as 9R or a poly-histidine such as 6H, and the like). The targeting ligand provides for (i) targeted binding to a cell surface protein, and (ii) engagement of a long endosomal recycling pathway. As such, when the targeting ligand engages the intended cell surface protein, the delivery molecule enters the cell (e.g., via endocytosis) but is preferentially directed away from the lysosomal degradation pathway.Type: GrantFiled: December 14, 2017Date of Patent: April 13, 2021Assignee: LIGANDAL, INC.Inventors: Andre Ronald Watson, Christian Foster
-
Patent number: 10954309Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of an Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO 26 or SEQ ID NO 27, wherein at least the alanine residue at the position corresponding to position 42 in SEQ ID NO:4-7 has been mutated to arginine and/or wherein at least the aspartic acid residue at the position corresponding to position 37 in SEQ ID NO:4-7 has been mutated to glutamic acid.Type: GrantFiled: November 11, 2015Date of Patent: March 23, 2021Assignee: Cytiva BioProcess R&D ABInventors: Gustav Rodrigo, Tomas Bjorkman, Mats Ander
-
Patent number: 10898542Abstract: The invention relates to a topical composition containing a variant of an OB-fold protein, and also to the process for preparing the same.Type: GrantFiled: December 24, 2019Date of Patent: January 26, 2021Assignee: AFFILOGICInventor: Olivier Kitten
-
Patent number: 10899822Abstract: Compositions are disclosed that include D-amino acid peptides and that are capable of specifically binding to at least one autoantibody against a G-protein coupled receptor. The autoantibody is produced in a patient having or being predisposed to a disease, condition, or disorder, and the autoantibody is capable of binding to a specific epitope of the G-protein coupled receptor. Methods of production and use of said compositions are also disclosed.Type: GrantFiled: November 27, 2019Date of Patent: January 26, 2021Assignee: The Board of Regents of the University of OklahomaInventor: David C. Kem
-
Patent number: 10857258Abstract: Disclosed are novel peptides with adhesive properties to various materials of biological or non-biological origins.Type: GrantFiled: September 25, 2017Date of Patent: December 8, 2020Assignee: SEWON BIOTECHNOLOGY INC.Inventor: Won-Joon Yoon
-
Patent number: 10849959Abstract: An injectable aqueous formulation as well as a dosage form is disclosed for use in intra-articular injection of a specific peptide of SEQ ID NO: 1, whereby the joint pain at the injection site is relieved in the absence of detectable changes in joint cartilage formation, with pain particularly relieved under certain stress motions such as walking down stairs.Type: GrantFiled: June 12, 2018Date of Patent: December 1, 2020Assignee: ORTHOTROPHIX, INC.Inventors: Yoshinari Kumagai, Dawn McGuire, Meghan Miller, David Rosen
-
Patent number: 10849958Abstract: Knee pain evaluation and management is carried out via intra-articular injections into a patient suffering from knee pain with the injection being comprised of water and a particularly defined peptide. After injection, knee pain is evaluated using a pain subscale such as Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) or Knee injury and Osteoarthritis Outcome Score (KOOS).Type: GrantFiled: June 12, 2018Date of Patent: December 1, 2020Assignee: ORTHOTROPHIX, INC.Inventors: Yoshinari Kumagai, Dawn McGuire, Meghan Miller, David Rosen